Loading
AZD6621 is an experimental T-cell engager from AstraZeneca in phase 2 trials for prostate cancer, aimed at CD3.
AZD6621 is a T-cell engager developed by AstraZeneca. Its target is CD3 (the sponsor names STEAP2 x CD3 x CD8). The sponsor states: AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study). ClinicalTrials.gov describes the intervention as: A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07192614, plans to enrol 52 participants with primary completion expected 2029-03-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study). Connects to CD3.
1.One arm of AZD6621 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD6621" OR ABSTRACT:"AZD6621") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD6621, not a curated reading list.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares CD3, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Prostate cancer and the tag pipeline.